High-Precision Mass Spectrometry-Based Immuno-Peptidomics Analysis and New Antigen Discovery

All short peptides presented on the cell surface via HLA-I and II molecules for T cell detection and recognition are referred to as the immunopeptidome. Immunopeptidomics analysis aims to study the dynamics and composition of type I and II immune peptides. In-depth characterization of the immunopeptidome can be applied to the development of new therapies for cancer, immune diseases, and infectious diseases.

Immune peptides are the entire set of peptides submitted by nucleated cells on type I and II proteins in the HLA or MHC antigen presentation pathway. It is essential in defining immunogenic epitopes in cell-mediated and humoral responses. Characterizing immune peptides can help us identify targets for personalized cancer immunotherapy, such as neoantigens derived from tumor-specific mutations or tumor-associated antigens. Additionally, new mRNA and peptide-based vaccines and cell-based therapies can be developed.

Biotech company Bright Peak's high-precision mass spectrometry-based immunopeptidomics analysis and neoantigen discovery one-stop solution includes our proprietary, highly sensitive immune peptide enrichment and identification protocol. We can assist you in identifying and recognizing over 10,000 type I peptides and over 10,000 type II peptides. Immunopeptidomics analysis through our optimized high-throughput immunopeptidomics analysis platform allows for repeatable identification and quantification from minimal sample material. This service can be applied to large-scale studies aimed at helping researchers find solutions for cancer, immune diseases, and infectious diseases, and delve into unknown targets.

High-precision mass spectrometry-based immunopeptidomics analysis and neoantigen discovery analysis strategy

The role of neoantigens in immunotherapy

 

Advantages and disadvantages of neoantigen prediction algorithms

 

One-stop solution for neoantigen discovery

Biotech company Bright Peak's one-stop solution for neoantigen discovery offers services including peptide synthesis, functional screening of neoantigen candidates for personalized cancer vaccines and T cell therapies, animal trials for personalized cancer vaccines, and clinical phase vaccine immunogenicity trials.

 

Research cases

 

 

 

Results delivery:

1. List of all identified immune peptides, neoantigen peptides, and tumor-associated antigen peptides
2. Quality analysis of immunopeptidomics data, such as data reports in research cases

 

About the sample

*If your sample volume is limited, please contact our business specialist for a free case analysis.